Table 3.

Clinical actionability by site of loss-of-function variants in genes other than BRCA1 and BRCA2

Gene	Total no. of carriers	Relatives tested (n)(carriers)	Breast cancer surveillance	Ovarian cancer surveillance	Other cancer surveillance
CHEK2	43	21 (9)	Yes	No increased risk	Yes; colon
PALB2	23	29 (12)	Yes	Insufficient evidence	Insufficient evidence
ATM	25	21 (7)	Yes	No increased risk	Insufficient evidence for PanCa/PrCa
TP53	20	12 (6)	Yes	No increased risk	Yes; multiple sites
RAD51C	10	2 (2)	Insufficient evidence	Yes	Insufficient evidence
NBN	6	6 (3)	Yes	Insufficient evidence	Insufficient evidence
PTEN	4	4 (1)	Yes	No increased risk	Yes; endometrium, thyroid, colon
RAD51D	4	2 (0)	Insufficient evidence	Yes	Insufficient evidence
PMS2	4	4 (2)	Insufficient evidence	Low/no increased risk	Yes; colon, endometrium,
MSH6	3	2 (0)	Insufficient evidence	Yes	Yes; endometrium, gastrointestinal tract
BRIP1	3	6 (1)	No increased risk	Yes	Insufficient evidence
MLH1	1	1 (0)	Insufficient evidence	Yes	Yes; endometrium, gastrointestinal tract
SDHB/C	2	1 (0)	Insufficient evidence	No increased risk	Yes; paragangliomas
Total	148	111	121	21	77
			Out of which 65 index	Out of which 18 index	Out of which 41 index

Bold numbers indicate statistically significant findings.